Epigenovo, a Uppsala University spinout, is commercializing scFFPE‑ATAC, a single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) samples. The startup demonstrated proof‑of‑concept in a Nature Communications paper and is fundraising to kit the workflow for broad adoption in translational and clinical epigenetics. The assay workflow uses a custom FFPE‑Tn5 transposase, combinatorial indexing and in‑vitro transcription to rescue damaged DNA, enabling single‑cell resolution in archival clinical specimens. Epigenovo claims the split‑and‑pool indexing strategy can generate tens of millions of cell barcodes per run, addressing a major translational barrier: extracting single‑cell epigenetic information from routine clinical materials. Management emphasized clinical translation as a priority: enabling single‑cell epigenetics in FFPE samples would expand discovery in tumor profiling, biomarker development and retrospective studies using large tissue archives.